Healthcare Services

Mucopolysaccharidosis Treatment Market Outlook 2026–2030 with Major Growth Drivers and Emerging Industry Trends

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Mucopolysaccharidosis Treatment Market Evolve From 2026 To 2030?

The mucopolysaccharidosis treatment market has experienced substantial expansion in recent years. It is projected to increase from $2.58 billion in 2025 to $2.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.7%. This historical progression can be linked to factors such as limited understanding of MPS disorders, high expenses associated with treatment, a slow integration of enzyme therapy, restricted opportunities for clinical trials, and a dependence on the international drug supply.

The mucopolysaccharidosis treatment market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $3.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This anticipated growth during the forecast period is fueled by factors such as the expansion of gene therapy research, increased investments in healthcare, enhanced rare disease screening initiatives, wider reimbursement coverage, and the advancement of precision medicine platforms. Key trends for this period encompass progress in enzyme replacement therapy, the rising popularity of stem cell transplantation, accelerated development of gene therapy methodologies, a heightened emphasis on early diagnosis and newborn screening, and the proliferation of specialized treatment facilities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11942&type=smp

What Major Drivers Are Influencing Demand In The Mucopolysaccharidosis Treatment Market?

The rising incidence of various types of mucopolysaccharidosis is projected to boost the mucopolysaccharidosis treatment market in the future. Mucopolysaccharide, a complex carbohydrate, builds up in body tissues due to a deficiency in the necessary digestive enzyme. Mucopolysaccharidosis (MPS) treatments can hinder disease progression by reducing glycosaminoglycan (GAG) accumulation, managing symptoms, and averting complications via diverse therapeutic methods. For example, in July 2024, data from the Orphanet Journal of Rare Diseases, a French peer-reviewed medical journal, indicated that the incidence of mucopolysaccharidosis IVa (MPS IVa) is estimated to be approximately 1 in 201,000 live births, although this number varies across different populations. Likewise, the birth prevalence of Mucopolysaccharidosis VI (MPS VI) is estimated to fall between 1 in 43,261 and 1 in 1,505,160, depending on the population. Consequently, the growing occurrence of different forms of mucopolysaccharidosis will propel the mucopolysaccharidosis treatment market.

Which Segment Areas Are Covered In The Mucopolysaccharidosis Treatment Market Analysis?

The mucopolysaccharidosis treatment market covered in this report is segmented –

1) By Treatment: Enzyme Replacement Therapy, Stem Cell Therapy

2) By Disease: Mucopolysaccharidosis- I, Mucopolysaccharidosis- II, Mucopolysaccharidosis-IV, Mucopolysaccharidosis-VI, Other Diseases

3) By Route Of Administration: Intravenous, Intracerebroventricular

4) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Enzyme Replacement Therapy: Idursulfase (Elaprase), Laronidase (Aldurazyme), Velaglucerase Alfa (Vpriv), Galsulfase (Naglazyme)

2) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT), Umbilical Cord Blood Transplantation, Gene Therapy Approaches

What Major Market Trends Are Driving Changes In The Mucopolysaccharidosis Treatment Market?

Major companies within the MPS II treatment market are prioritizing the creation of advanced solutions, such as AAV gene therapies, to target the fundamental genetic causes of the disorder and achieve sustained neurological correction. An AAV gene therapy represents a precise genetic intervention that utilizes adeno-associated viral vectors to introduce functional genes into central nervous system cells, allowing for the continuous production of proteins that are either absent or deficient. For example, in August 2025, REGENXBIO Inc., a US-based biotechnology company, disclosed that the United States Food and Drug Administration had prolonged its review period for RGX-121. This extension came after the submission of longer-term clinical data from all pivotal-study participants, which remained consistent with previously observed biomarker and neurodevelopmental results. The satisfactory pre-license inspections and absence of safety issues signify continued regulatory advancement, underscoring the therapy’s capability to serve as the inaugural one-time treatment for the neurological manifestations of MPS II.

Which Global Companies Are Actively Competing In The Mucopolysaccharidosis Treatment Market?

Major companies operating in the mucopolysaccharidosis treatment market are BioMarin Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Abeona Therapeutics Inc., Immusoft Corporation, Neurogene Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Denali Therapeutics Inc., Passage Bio Inc., Homology Medicines Inc., AVROBIO Inc., Rocket Pharmaceuticals Inc., Taysha Gene Therapies Inc., Freeline Therapeutics Holdings plc, 4D Molecular Therapeutics Inc., Sio Gene Therapies Inc., SpliceBio S.L., LogicBio Therapeutics Inc., Orchard Therapeutics plc, Asklepios BioPharmaceutical Inc.

Read the full mucopolysaccharidosis treatment market report here:

https://www.thebusinessresearchcompany.com/report/mucopolysaccharidosis-treatment-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Mucopolysaccharidosis Treatment Market?

North America was the largest region in the mucopolysaccharidosis treatment market in 2025. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Mucopolysaccharidosis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11942&type=smp

Browse Through More Reports Similar to the Global Mucopolysaccharidosis Treatment Market 2026, By The Business Research Company

Contrast Media Global Market Report

https://www.thebusinessresearchcompany.com/report/contrast-media-global-market-report

Medical Imaging Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-imaging-global-market-report

Portable Magnetic Resonance Imaging Mri Global Market Report

https://www.thebusinessresearchcompany.com/report/portable-magnetic-resonance-imaging-mri-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795